NCT00002197已完成不适用
1592U89 Open-Label Protocol for Pediatric Patients With HIV Infection.
Glaxo Wellcome1 个研究点 分布在 1 个国家目标入组 250 人开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 250
- 试验地点
- 1
研究概览
简要总结
The purpose of this study is to see if it is safe to give 1592U89 to children (aged 6 months until 14th birthday) with advanced HIV infection who have few treatment options available. The study also examines the effect 1592U89 has on the levels of HIV in the blood.
详细描述
This is an open-label, non-randomized study. All patients will be treated with 1592U89. Additionally, since optimal therapy usually includes the combined use of 2 or more antiretroviral agents in advanced patients, other novel antiretroviral therapies may be accessed through commercial means or via compassionate use programs. NOTE: 1592U89 should not be administered as a single new agent added to a failing treatment regimen.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Months 至 13 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Concurrent Medication:
- •Intravenous immunoglobulin G.
- •Erythropoietin, granulocyte colony stimulating factor and granulocyte macrophage colony stimulating factor, for the management of hematologic toxicity.
- •Patients must have:
- •Documented HIV infection.
- •High risk for disease progression or mortality as defined by either of the following:
- •Viral load > 100,000 copies/ml and CD4 cells < 15% of total lymphocyte count despite at least 4 weeks of therapy with commercially available antiretrovirals or as a result of no therapy due to treatment-limiting toxicity of ZDV, 3TC, and ddI; or HIV-associated encephalopathy refractory to ZDV-containing regimen.
- •No access to any 1592U89 pediatric study where the patient could qualify for inclusion.
- •Parent or legal guardian with the ability to understand and provide written consent for the patient to participate in the trial. Study patients over 13 years should also give written informed consent whenever possible.
排除标准
- •Co-existing Condition:
- •Patients with any of the following symptoms or conditions are excluded:
- •In the investigator's opinion, the patient is unlikely to comply with the requirements of the study.
- •Renal failure requiring dialysis.
- •Hepatic failure evident by Grade 3 or 4 hyperbilirubinemia and AST > 10 X upper limits of normal.
- •Life-threatening infection or other chronic disease that may interfere with taking 1592U89 or compromise the patient's safety.
- •Patients with the following prior conditions are excluded:
- •Documented hypersensitivity to 1592U89 or any other nucleoside analogue.
- •See Inclusion - General Criteria.
研究者
研究点 (1)
Loading locations...
相似试验
招募中
3 期
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia BHemophilia BHemophilia ANCT05611801Pfizer100
终止
3 期
Open-Label Safety and PK Study of ER Hydromorphone Tablets in Opioid-Tolerant Pediatric Chronic Pain PatientsChronic PainNCT02321319Mallinckrodt5
已完成
4 期
Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum MalariaMalaria, FalciparumNCT00529867Dafra Pharma267
已完成
不适用
A Study of 1592U89 in HIV-Infected AdultsHIV InfectionsNCT00002200Glaxo Wellcome
招募中
3 期
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia BHemophilia A Hemophilia BJPRN-jRCT2071220116Kawai Norisuke100